Anxiety disorders are the most common class of mental disorders, characterized by excessive fear, anxiety, and related behavioral disturbances. While fear is an adaptive response to real or perceived threat, anxiety disorders involve disproportionate, persistent reactions that impair functioning. The distinction lies in intensity, duration, impairment, and control. Anxiety disorders affect approximately 30% of the population at some point in life. Women are twice as likely as men to be affected. Onset is typically in childhood or early adolescence.

Stress and anxiety — Anxiety disorders are the most prevalent mental health conditions, affecting nearly 30% of adults at some point in their lives. Source: Unsplash.

Neurobiology. The amygdala is central to fear processing — it activates the HPA axis and sympathetic nervous system through connections to the hypothalamus and brainstem. The prefrontal cortex, particularly the ventromedial PFC, exerts inhibitory control over the amygdala. In anxiety disorders, this top-down regulation is impaired. Key neurotransmitters include serotonin, norepinephrine, and GABA. The neuropeptide substance P also contributes.

Generalized Anxiety Disorder (GAD)

GAD is characterized by excessive anxiety and worry occurring more days than not for at least six months, about a number of events or activities. The worry is difficult to control and associated with three or more physical symptoms: restlessness, easy fatigability, difficulty concentrating, irritability, muscle tension, and sleep disturbance. Lifetime prevalence is 5–7%. Onset is gradual in early adulthood, and the course is chronic with fluctuating severity.

Treatment. First-line pharmacotherapy: SSRIs (paroxetine, escitalopram, sertraline) and SNRIs (venlafaxine, duloxetine). Pregabalin and buspirone are alternative agents. Psychological treatment: cognitive behavioral therapy with applied relaxation, cognitive restructuring, and worry exposure. Mindfulness-based interventions reduce relapse. Both pharmacotherapy and CBT are effective; combination therapy is superior for non-responders.

Panic Disorder

Panic disorder is characterized by recurrent, unexpected panic attacks — abrupt surges of intense fear that peak within minutes — followed by persistent concern about additional attacks or maladaptive avoidance. Panic attack symptoms include palpitations, sweating, trembling, shortness of breath, chest pain, nausea, dizziness, paresthesias, derealization, fear of losing control, and fear of dying. Panic disorder is commonly accompanied by agoraphobia — avoidance of situations where escape might be difficult (public transportation, crowds, enclosed spaces, being alone outside).

Lifetime prevalence is 3–5%, with onset in late adolescence or early adulthood. Patients frequently present to emergency departments with acute physical symptoms before receiving a psychiatric diagnosis.

Treatment. SSRIs and SNRIs are first-line. Cognitive behavioral therapy with interoceptive exposure (deliberately inducing panic sensations to reduce fear of bodily symptoms) and in vivo exposure to avoided situations is highly effective. Panic-focused psychodynamic therapy also has evidence.

⚠ Clinical Correlation

Panic attacks mimic life-threatening conditions: myocardial infarction (chest pain, palpitations, dyspnea), asthma exacerbation, pulmonary embolism, hyperthyroidism, and pheochromocytoma. Emergency evaluation — ECG, cardiac enzymes, thyroid function, and pulmonary assessment — may be needed for first presentations or atypical symptoms. Once organic causes are excluded, reassurance and psychoeducation about the benign nature of panic attacks are important. Benzodiazepines (alprazolam, clonazepam) provide rapid relief for acute panic but carry addiction risk and are not recommended as monotherapy.

Marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others. The individual fears being negatively evaluated, humiliated, or rejected. Social situations consistently provoke fear or anxiety, are avoided or endured with intense distress, and cause significant functional impairment. Performance-only specifier: fear is restricted to speaking or performing in public. Lifetime prevalence is 7–13%, making it the most common anxiety disorder. Onset is typically in early adolescence, and the course is chronic without treatment.

Treatment. SSRIs (paroxetine, sertraline, fluvoxamine) and the SNRI venlafaxine are first-line pharmacotherapy. CBT with exposure therapy (systematic, graduated exposure to feared social situations) and social skills training is highly effective. Beta-blockers (propranolol) are used for performance anxiety but not for generalized social anxiety.

Specific Phobias

Marked fear or anxiety about a specific object or situation (flying, heights, animals, receiving an injection, blood). The phobic stimulus almost always provokes immediate fear or anxiety, is actively avoided or endured with intense fear, and causes significant distress or impairment. Lifetime prevalence is 7–9%. The most effective treatment is exposure therapy — systematic, repeated confrontation with the feared stimulus in a controlled therapeutic context. Pharmacotherapy is generally not indicated.

Agoraphobia

Fear or anxiety about two or more of the following: public transportation, open spaces, enclosed spaces, standing in line or being in a crowd, and being outside the home alone. The individual fears these situations because escape might be difficult or help unavailable in the event of panic-like symptoms or other incapacitating or embarrassing situations. Agoraphobia causes avoidance, requires a companion, or is endured with intense fear. It frequently co-occurs with panic disorder but can be diagnosed independently.

Selective Mutism

A rare childhood disorder in which a child consistently fails to speak in specific social situations where speaking is expected (e.g., school), despite speaking in other situations. It causes academic and social impairment. Often associated with social anxiety. Treatment involves behavioral interventions (reward systems, stimulus fading), family therapy, and school accommodations.

★ Key Concept

Cognitive behavioral therapy is the most empirically supported psychological treatment across all anxiety disorders. Core components include: psychoeducation about the nature of anxiety; cognitive restructuring to identify and challenge threat-related beliefs (catastrophizing, overestimation of danger); exposure therapy — systematic, repeated confrontation with feared stimuli to promote habituation and extinction learning; and relapse prevention. Exposure can be in vivo (real-life), imaginal (imagining the feared scenario), or interoceptive (inducing feared bodily sensations). The inhibitory learning model emphasizes that exposure does not erase fear but creates new, competing safety memories.

Summary

Anxiety disorders are the most prevalent mental health conditions, each with distinct patterns of fear and avoidance. GAD involves chronic worry about multiple domains. Panic disorder features acute, intense episodes of fear accompanied by physical symptoms. Social anxiety centers on fear of negative evaluation. Specific phobias and agoraphobia involve fear and avoidance of specific situations or places. SSRIs/SNRIs and CBT (particularly exposure therapy) are effective first-line treatments across the spectrum. Early recognition and treatment prevent chronic disability and secondary depression.